GLP-1 users who maintain at least 80% adherence to therapy see greater cost reductions than those with lower adherence
Modeling based on current utilization suggests these price reductions could generate $932.7 million in savings, sufficient to offset treatment costs for approximately 550 000 additional beneficiaries eligible for expanded #obesity coverage
In the 1980s, researchers identified a hormone in the human gut called GLP-1 that triggers the release of insulin, which controls blood sugar levels
And, of course, we provide great analytics so you can track your progress over time
Mihovil I, Radic B, Brcic I, Drmic D, Vukoja I, Boban Blagaic A, et al
Cardiovascular Considerations Weight loss itself provides cardiovascular benefits, and Retatrutide benefits may include additional positive effects on heart health markers